Timing, Patterns and Predictors of 90-Day Readmission Rate after Robotic Radical Cystectomy.


Journal

The Journal of urology
ISSN: 1527-3792
Titre abrégé: J Urol
Pays: United States
ID NLM: 0376374

Informations de publication

Date de publication:
02 2021
Historique:
pubmed: 10 10 2020
medline: 26 2 2021
entrez: 9 10 2020
Statut: ppublish

Résumé

We examine the timing, patterns and predictors of 90-day readmission after robotic radical cystectomy. From September 2009 to March 2017, 271 consecutive patients undergoing robotic radical cystectomy with intent to cure bladder cancer (intracorporeal diversion 253, 93%) were identified from our prospectively collated institutional database. Readmission was defined as any subsequent inpatient admission or unplanned visit occurring within 90 days from discharge after the index hospitalization. Multiple readmissions were defined as 2 or more readmissions within a 90-day period. Logistic regression analysis was used to identify independent factors related to single and multiple 90-day readmissions. A total of 78 (28.8%) patients were readmitted at least once within 90 days after discharge, of whom 20 (25.6%) reported multiple readmissions. The cumulative duration of readmission was 6.2 (6.17) days with 6 (7.6%) patients having less than 24 hours readmission. Metabolic, infectious, genitourinary and gastrointestinal complications were identified as the primary cause of readmission in 39.5%, 23.5%, 22.3% and 17%, respectively. Fifty percent of readmissions occurred in the first 2 weeks after hospital discharge. On multivariable logistic regression analysis in-hospital infections (OR 2.85, p=0.001) were independent predictors for overall readmission. Male gender (OR 3.5, p=0.02) and in-hospital infections (OR 4.35, p=0.002) were independent predictors for multiple readmissions. The 90-day readmission rate following robotic radical cystectomy is significant. In-hospital infections and male gender were independent factors for readmission. Most readmissions occurred in the first 2 weeks following discharge, with metabolic derangements and infections being the most common causes.

Identifiants

pubmed: 33035137
doi: 10.1097/JU.0000000000001387
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

491-499

Auteurs

Giovanni E Cacciamani (GE)

USC Institute of Urology, Keck Medicine of USC, University of Southern California, Los Angeles, California.

Luis Medina (L)

USC Institute of Urology, Keck Medicine of USC, University of Southern California, Los Angeles, California.

Michael Lin-Brande (M)

USC Institute of Urology, Keck Medicine of USC, University of Southern California, Los Angeles, California.

Alessandro Tafuri (A)

USC Institute of Urology, Keck Medicine of USC, University of Southern California, Los Angeles, California.

Ryan S Lee (RS)

USC Institute of Urology, Keck Medicine of USC, University of Southern California, Los Angeles, California.

Saum Ghodoussipour (S)

USC Institute of Urology, Keck Medicine of USC, University of Southern California, Los Angeles, California.

Akbar N Ashrafi (AN)

USC Institute of Urology, Keck Medicine of USC, University of Southern California, Los Angeles, California.

Matthew Winter (M)

USC Institute of Urology, Keck Medicine of USC, University of Southern California, Los Angeles, California.

Nariman Ahmadi (N)

USC Institute of Urology, Keck Medicine of USC, University of Southern California, Los Angeles, California.

Nieroshan Rajarubendra (N)

USC Institute of Urology, Keck Medicine of USC, University of Southern California, Los Angeles, California.

Gus Miranda (G)

USC Institute of Urology, Keck Medicine of USC, University of Southern California, Los Angeles, California.

Andre De Castro Abreu (A)

USC Institute of Urology, Keck Medicine of USC, University of Southern California, Los Angeles, California.

Andre Berger (A)

USC Institute of Urology, Keck Medicine of USC, University of Southern California, Los Angeles, California.

Monish Aron (M)

USC Institute of Urology, Keck Medicine of USC, University of Southern California, Los Angeles, California.

Inderbir S Gill (IS)

USC Institute of Urology, Keck Medicine of USC, University of Southern California, Los Angeles, California.

Mihir Desai (M)

USC Institute of Urology, Keck Medicine of USC, University of Southern California, Los Angeles, California.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH